Bad news for Nuvelo Inc.: Its partnered thrombolytic drug alfimeprase failed two Phase III studies, one in acute peripheral arterial occlusion (PAO) and the other in catheter occlusion (CO). (BioWorld Today)
Bad news for Nuvelo Inc.: Its partnered thrombolytic drug alfimeprase failed two Phase III studies, one in acute peripheral arterial occlusion (PAO) and the other in catheter occlusion (CO). (BioWorld Today)
Vanda Pharmaceuticals Inc.'s positive Phase III results on the investigational schizophrenia drug iloperidone were well received by every measure, with the company's stock value soaring 68.7 percent Thursday, fueled by both the data and buyout rumors. (BioWorld Today)
Vanda Pharmaceuticals Inc.'s positive Phase III results on the investigational schizophrenia drug iloperidone were well received by every measure, with the company's stock value soaring 68.7 percent Thursday, fueled by both the data and buyout rumors. (BioWorld Today)
